Overview

Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens

Status:
Unknown status

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

Phase IIb clinical trial to determine if resistance to a lenalidomide containing regimen can be overcome by the addition of vorinostat, in patients with relapsed and refractory multiple myeloma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hackensack Meridian Health
Hackensack University Medical Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide
Vorinostat